Daisy Gemma Yan Thompson-Lake

Daisy Gemma Yan Thompson-Lake

Auto-generated profile, based on publicly available information

Daisy Gemma Yan Thompson-Lake

Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville, VA, United States

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in British Journal of Psychology
Verified
Journal Article
Closed access
PDF file
JWJamie Ward
Jamie Ward
DTDaisy Thompson‐Lake
Daisy Thompson‐Lake
RERoxanne Ely
Roxanne Ely
FKFlora Kaminski
Flora Kaminski

1 September 2014 in Bulletin of the Menninger Clinic
Verified
Journal Article
Closed access
SBSelina Baeza-Loya
Selina Baeza-Loya
HVHumsini Viswanath
Humsini Viswanath
ACAsasia Carter
Asasia Carter
DMDavid L. Molfese
David L. Molfese
KVKenia M. Velasquez
Kenia M. Velasquez
RSRamiro Salas
Ramiro Salas

25 November 2014 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
JMJames J Mahoney
James J Mahoney
DTDaisy Gy Thompson-Lake
Daisy Gy Thompson-Lake
KCKimberly Cooper
Kimberly Cooper
CVChristopher D Verrico
Christopher D Verrico
TNThomas F Newton
Thomas F Newton
RGRichard De La Garza
Richard De La Garza
Previous research has focused on developing theories of addiction that may explain behavior in cocaine- and methamphetamine-dependent individuals. The primary goal of this report was to compare and contrast the prevalence of self-reported measures of impulsivity, depression, lifetime stress and sensation-seeking in healthy controls versus individuals with cocaine or methamphetamine use disorders. Twenty-nine individuals with cocaine use disorders and 31 individuals with methamphetamine use disorders were matched with 31 healthy control participants on several demographic variables. All participants were administered behavioral questionnaires including the Barrett Impulsiveness Scale (assessing impulsivity), Beck Depression Inventory II (assessing depression), Life Stressor Checklist–Revised (assessing lifetime stress) and the Impulsive Sensation Seeking Scale (assessing sensation-seeking). When compared to healthy controls, individuals with cocaine and methamphetamine use disorders had significantly higher levels of impulsivity and sensation-seeking. In addition, when compared to healthy controls, individuals with cocaine use disorders had significantly higher Beck Depression Inventory II scores, while individuals with methamphetamine use disorders had significantly higher Life Stressor Checklist–Revised scores. The results revealed that there were significantly higher levels of impulsivity, depression and sensation-seeking in cocaine users and significantly higher impulsivity, lifetime stress and sensation-seeking in methamphetamine users when compared to healthy controls.

1 December 2014 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
RSRicky Savjani
Ricky Savjani
KVKenia M. Velasquez
Kenia M. Velasquez
DTDaisy Gemma Yan Thompson-Lake
Daisy Gemma Yan Thompson-Lake
PBPhilip Rupert Baldwin
Philip Rupert Baldwin
DEDavid M. Eagleman
David M. Eagleman
RSRamiro Salas
Ramiro Salas

1 November 2016 in Psychiatry Research
Verified
Journal Article
Closed access
RGRichard De La Garza
Richard De La Garza
JYJin H. Yoon
Jin H. Yoon
DTDaisy G.Y. Thompson-Lake
Daisy G.Y. Thompson-Lake
CHColin N. Haile
Colin N. Haile
JEJoel D. Eisenhofer
Joel D. Eisenhofer
JMJames J. Mahoney
James J. Mahoney

25 May 2016 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
CRChristopher Rodgman
Christopher Rodgman
CVChristopher D. Verrico
Christopher D. Verrico
MHManuela Holst
Manuela Holst
DTDaisy Thompson-Lake
Daisy Thompson-Lake
CHColin N. Haile
Colin N. Haile
TNThomas F. Newton
Thomas F. Newton
Serotonin and norepinephrine reuptake inhibitors are effective first-line agents for the treatment of posttraumatic stress disorder (PTSD), but treatment is associated with a range of side effects that limit treatment adherence. Prazosin, an α1-noradrenergic antagonist with a half-life of roughly 2-3 hours, has shown promise in the treatment of sleep disturbance and nightmares. Doxazosin extended release (XL) is also an α1-noradrenergic antagonist but with a half-life of approximately 15-19 hours. We conducted a double-blind, placebo-controlled, within-subjects trial to characterize the impact of doxazosin XL on PTSD symptoms. Participants (N = 8) were diagnosed using DSM-IV criteria. They completed the study twice, once during treatment with doxazosin XL and once during treatment with matched placebo, with a 2-week washout separating the 2 episodes. Doxazosin XL was titrated from 4 mg/d to 16 mg/d over 12 days. After 4 days of treatment at 16 mg/d or the equivalent number of placebo capsules, PTSD symptoms were assessed using the Clinician-Administered PTSD Scale (CAPS17) and the PTSD Checklist-Military version (PCL-M). Repeated measures analysis of variance were used to evaluate effects of treatment, time, and treatment × time. This study was run from November 20, 2013, to June 31, 2014. Doxazosin XL treatment was associated with a nonsignificant treatment × time reduction in ratings on the CAPS hyperarousal subscale (P < .10) (but not on the CAPS Total score) and with significant treatment × time reductions in PCL-M ratings (P = .002). Doxazosin XL may be an effective alternative to prazosin for the treatment of some PTSD symptoms. ClinicalTrials.gov Identifier:NCT02308202.